Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

Stock Information for Quanterix Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quanterix Corporation

Quanterix Expands Reach with IVD and Large Reference Labs
AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders
Quanterix to Present at Goldman Sachs Global Healthcare Conference
Quanterix Releases Financial Results for the First Quarter of 2025
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders
Quanterix and Akoya Biosciences Announce Amended Merger Agreement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.